Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors

Bone Marrow Transplantation

Volumn 33, Issue 11, 2004, Pages 1115-1121

  Schattenberg, A ^a   van der Meer, A ^a   Preijers, F ^a   Schaap, N ^a   Rinkes, M ^a   van der Maazen, R ^a   Allebes, W ^a   Joosten, I ^a   de Witte, Th ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ATG; Lymphocyte depleted SCT; VUD

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IDARUBICIN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DEATH; DISEASE SEVERITY; DONOR; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INCIDENCE; LYMPH NODE IRRADIATION; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RECIPIENT; REFRACTORY ANEMIA; RELAPSE; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VOLUNTEER; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; DRUG EVALUATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 2942722311     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704490     Document Type: Article

References (20)

1. O'Reilly RJ. Allogeneic bone marrow transplantation: current status and future directions. Blood 1983; 62: 941-964.
2. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med 1992; 116: 505-512.
3. Bacigalupo A, Oneto R, Bruno B et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol 2000; 103: 19-25.
4. Hansen JA, Yamamoto K, Petersdorf E, Sasazuki T. The role of HLA matching in hematopoietic cell transplantation. Rev Immunogenet 1999; 1: 359-373.
5. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
6. Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341-1347.
7. Preijers FW, van Hennik PB, Schattenberg A et al. Counter-flow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells. Bone Marrow Transplant 1999; 23: 1061-1070.
8. Van der Meer A, Joosten I, Ruiter J, Allebes WA. A single [3H]thymidine-based limiting dilution analysis to determine HTLp and CTLp frequencies for bone marrow donor selection. Bone Marrow Transplant 1997; 20: 149-155.
9. Van der Meer A, Joosten I, Schattenberg A et al. Cytotoxic T-lymphocyte precursor frequency (CTLp-f) as a tool for distinguishing permissible from non-permissible class I mismatches in T-cell-depleted allogeneic bone marrow transplantation. Br J Haematol 2000; 111: 685-694.
10. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
11. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. Am J Med 1980; 69: 204-217.
12. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
13. Schaap N, Schattenberg A, Bar B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol 1997; 98: 750-759.
14. Soiffer RJ, Mauch P, Tarbell NJ et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 1991; 7: 23-33.
15. McGlave PB, Shu XO, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95: 2219-2225.
16. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
17. Bacigalupo A, Lamparelli T, Gualandi F et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002; 8: 656-661.
18. Remberger M, Storer B, Ringden O, Anasetti C. Between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391-397.
19. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216.
20. Van Esser JWJ, Niesters HGM, Van der Holt B et al. Prevention of Ebstein-Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic hematopoietic stem cell transplantation. Blood 2002; 99: 4364-4369.